Skip to content
Wired News Engine – Lifestyle
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 7, 2026
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
July 30, 2026
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
July 23, 2026
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
July 21, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
July 9, 2026
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
July 1, 2026
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
June 15, 2026
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
June 15, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
June 15, 2026
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
June 15, 2026
1
2
3
Next Page
→